NEW YORK, Aug. 1 - SRI International announced today that it will lead a drug development collaboration called PharmaSTART that will assist four California-based institutions in creating drug discovery plans.
The collaboration will include
According to Glenn Rice, vice president of SRI's Biosciences Division, there is a "major gap" in the translation of genomics and proteomics initiatives into new drugs. SRI hopes to bridge that gap by committing $500,000 and 1,000 hours of consulting time to PharmaSTART, which Rice said in a statement would "catalyze the emergence of new collaborations, new drug development initiatives, and new funding sources" among the participants. In particular, SRI will train principal investigators in the procedures necessary to win NIH and other government-funded grants.